Parametric Portfolio Associates LLC lowered its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 64.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,520 shares of the company’s stock after selling 54,139 shares during the period. Parametric Portfolio Associates LLC’s holdings in Amneal Pharmaceuticals were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently added to or reduced their stakes in AMRX. Bank of Montreal Can raised its position in shares of Amneal Pharmaceuticals by 87.5% during the second quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock valued at $60,000 after buying an additional 3,954 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $177,000. Atria Investments LLC bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $240,000. Appleton Partners Inc. MA bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $254,000. Finally, Acadian Asset Management LLC raised its position in shares of Amneal Pharmaceuticals by 96.3% during the second quarter. Acadian Asset Management LLC now owns 45,000 shares of the company’s stock valued at $323,000 after buying an additional 22,073 shares during the last quarter. Hedge funds and other institutional investors own 34.79% of the company’s stock.
Shares of AMRX opened at $2.99 on Friday. The company’s fifty day moving average is $3.03 and its 200 day moving average is $6.48. Amneal Pharmaceuticals Inc has a fifty-two week low of $2.27 and a fifty-two week high of $21.22. The stock has a market capitalization of $900.26 million, a PE ratio of 3.15, a P/E/G ratio of 0.85 and a beta of 1.51. The company has a debt-to-equity ratio of 3.66, a quick ratio of 1.41 and a current ratio of 2.17.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.05). Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The business had revenue of $404.60 million during the quarter, compared to the consensus estimate of $420.12 million. During the same quarter in the prior year, the firm posted $0.24 EPS. The company’s revenue for the quarter was down 12.5% on a year-over-year basis. As a group, research analysts forecast that Amneal Pharmaceuticals Inc will post 0.51 earnings per share for the current year.
AMRX has been the topic of several recent analyst reports. Piper Jaffray Companies upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $11.00 price objective on the stock in a research report on Monday, July 8th. SunTrust Banks reiterated a “buy” rating and set a $5.00 price objective on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Svb Leerink upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their price objective for the company from $11.00 to $5.00 in a research report on Monday, July 22nd. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Amneal Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $9.00.
In other news, VP Andrew S. Boyer acquired 66,666 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was bought at an average cost of $2.89 per share, with a total value of $192,664.74. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ted C. Nark acquired 50,000 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were purchased at an average cost of $2.39 per share, with a total value of $119,500.00. The disclosure for this purchase can be found here. Insiders purchased 1,788,966 shares of company stock worth $5,377,057 in the last 90 days. 26.34% of the stock is currently owned by company insiders.
Amneal Pharmaceuticals Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.